Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.…
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
Adlai Nortye Group (NASDAQ: ANL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 109 employees.
The shares were at 8.550 USD on 20 November 2026, up 431.1% over 52 weeks. Its 52-week range is 0.8790 USD to 17.25 USD: the price is 50.4% below the high and 872.7% above the low.
Its market capitalisation is 550.60M USD.
Adlai Nortye Group reports return on equity of 426.9% and an operating margin of -123.5%.
It holds more cash than debt, a net cash position of 206.12M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 29.50 USD is 245.0% above the current price.
No upcoming events tracked.